CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals USA, Inc.

1:17-cv-00393

Overview

Case Number 1:17-cv-00393
Filing Date 2017-04-07
Status Terminated
Termination Date 2018-02-26
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Teva Pharmaceuticals USA, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Novartis Pharmaceuticals Corporation Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 11 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials 6 proceedings
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (11): πŸ‡ͺπŸ‡Ί Europe GB πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (6 found):
PTAB: 6
USPTO PTAB Trial 2018-01-17
IPR2018-00507

Hikma Pharmaceuticals PLC v. Novartis Pharmaceuticals Corporation

U.S. Continuation Sibling (8410131)
Status: Terminated-Settled
USPTO PTAB Trial 2017-06-12
IPR2017-01592

Breckenridge Pharmaceutial, Inc. v. Novartis Pharmaceuticals Corporation

U.S. Continuation Sibling (8410131)
Status: Terminated-Settled
USPTO PTAB Trial 2017-03-13
IPR2017-01078

West-Ward Pharmaceuticals International Limited v. Novartis AG

U.S. Continuation Sibling (9006224)
Status: Terminated-Settled
USPTO PTAB Trial 2017-03-10
IPR2017-01063

Argentum Pharmaceuticals LLC et al. v. Novartis AG

U.S. Continuation Sibling (9006224)
Status: Final Written Decision
USPTO PTAB Trial 2016-07-22
IPR2016-01479

Par Pharmaceutical, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (9006224)
Status: Final Written Decision
USPTO PTAB Trial 2016-07-19
IPR2016-01461

Roxane Laboratories, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (9006224)
Status: Institution Denied
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

4 Patents

There are 4 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US9006224
Neuroendocrine tumor treatment
Filed: 2006-11-20
Issued: 2015-04-14
Active (1.6 yrs remaining) +589d PTA
Expires: 2028-07-01
US8410131
Cancer treatment
Filed: 2002-02-18
Issued: 2013-04-02
Expired (Term Ended) +1352d PTA
Expires: 2025-11-01
US8778962
Treatment of solid tumors with rapamycin derivatives
Filed: 2012-07-11
Issued: 2014-07-15
Active (5.6 yrs remaining)
Expires: 2032-07-11
US8436010
Treatment of solid tumors with rapamycin derivatives
Filed: 2012-02-23
Issued: 2013-05-07
Expired (Term Ended)
Expires: 2022-02-22

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+589 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Docket Entries

(26 total)
Pleading / Complaint

COMPLAINT filed against Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2118447.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, B, C, and D, # 2 Civil Cover Sheet)(crb) (Entered: 04/10/2017)

Entry #1 • 2017-04-07
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (crb) (Entered: 04/10/2017)

Entry #2 • 2017-04-07
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 2/21/2017. Date of Expiration of Patent: See Attachment.Thirty Month Stay Deadline: 8/21/2019. (crb) (Entered: 04/10/2017)

Entry #3 • 2017-04-07
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,006,224; 8,410,131; 8,778,962; 8,436,010;. (crb) (Entered: 04/10/2017)

Entry #4 • 2017-04-07
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (crb) (Entered: 04/10/2017)

Entry #5 • 2017-04-07
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc